

# Shonit Punwani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2880654/publications.pdf>

Version: 2024-02-01

43  
papers

3,930  
citations

361045

20  
h-index

301761

39  
g-index

45  
all docs

45  
docs citations

45  
times ranked

6005  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	13.9	2,036
2	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
3	Microstructural Characterization of Normal and Malignant Human Prostate Tissue With Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2015, 50, 218-227.	3.5	137
4	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. <i>BJU International</i> , 2018, 122, 13-25.	1.3	106
5	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , 2019, 124, 431-440.	1.3	93
6	Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. <i>European Radiology</i> , 2019, 29, 4754-4764.	2.3	55
7	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. <i>Radiology</i> , 2019, 291, 391-397.	3.6	52
8	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	3.7	51
9	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	5.2	50
10	Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 424.e9-424.e16.	0.8	44
11	Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. <i>Insights Into Imaging</i> , 2021, 12, 59.	1.6	43
12	INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. <i>BMC Cancer</i> , 2016, 16, 816.	1.1	40
13	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. <i>Health Technology Assessment</i> , 2019, 23, 1-270.	1.3	34
14	Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. <i>BJU International</i> , 2021, 127, 304-306.	1.3	32
15	Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. <i>European Radiology</i> , 2022, 32, 879-889.	2.3	32
16	A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. <i>European Urology Oncology</i> , 2020, 3, 262-269.	2.6	28
17	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. <i>European Urology</i> , 2020, 78, 503-511.	0.9	27
18	Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. <i>British Journal of Radiology</i> , 2018, 91, 20170645.	1.0	23

#	ARTICLE	IF	CITATIONS
19	VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific moulds for histological and MR alignment. <i>NMR in Biomedicine</i> , 2019, 32, e4073.	1.6	22
20	Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. <i>British Journal of Radiology</i> , 2022, 95, 20210415.	1.0	22
21	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Tj ETQq1 1 0.784314 rgBT /Over	1.0	22
22	VERDICT-AMICO: Ultrafast fitting algorithm for non-invasive prostate microstructure characterization. <i>NMR in Biomedicine</i> , 2019, 32, e4019.	1.6	19
23	Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. <i>Medical Image Analysis</i> , 2021, 73, 102153.	7.0	19
24	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. <i>European Urology</i> , 2020, 78, 155-160.	0.9	18
25	Harnessing Uncertainty in Domain Adaptation for MRI Prostate Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2020, , 510-520.	1.0	17
26	Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T <sub>2</sub> MR Images. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 910-917.	1.9	16
27	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. <i>BMJ Open</i> , 2018, 8, e024941.	0.8	14
28	Standardisation of prostate multiparametric MRI across a hospital network: a London experience. <i>Insights Into Imaging</i> , 2021, 12, 52.	1.6	11
29	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. <i>Cancers</i> , 2021, 13, 1985.	1.7	10
30	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	2.0	10
31	AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning. <i>Cancers</i> , 2021, 13, 6138.	1.7	10
32	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. <i>BMC Medical Imaging</i> , 2019, 19, 90.	1.4	9
33	Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer. <i>European Radiology</i> , 2019, 29, 4150-4159.	2.3	8
34	Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. <i>BJU International</i> , 2020, 125, 391-398.	1.3	8
35	Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. <i>Molecular Oncology</i> , 2021, 15, 2565-2579.	2.1	5
36	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. <i>Diagnostics</i> , 2022, 12, 231.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study. <i>European Urology Open Science</i> , 2021, 30, 16-24.	0.2	4
38	Unsupervised Domain Adaptation with Semantic Consistency Across Heterogeneous Modalities for MRI Prostate Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2021, , 90-100.	1.0	2
39	Synthesizing VERDICT Maps from Standard DWI Data Using GANs. <i>Lecture Notes in Computer Science</i> , 2021, , 58-67.	1.0	1
40	Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens. <i>Blood</i> , 2015, 126, 1850-1850.	0.6	1
41	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1065-1066.	0.2	0
42	Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. <i>BMJ Open</i> , 2022, 12, e059847.	0.8	0
43	Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models. <i>Diagnostics</i> , 2022, 12, 1631.	1.3	0